Researchers suggest FDA needs authority to require pediatric studies for orphan drugs
Regulatory NewsJoanne S. Eglovitch
Clinical TrialsPediatric productsPharmaceuticalsProduct developmentResearch, Design and DevelopmentUnited StatesUS Food and Drug Administration (FDA)